Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1972 1
1977 3
1980 1
1983 1
1987 1
1988 1
1989 6
1990 2
1991 4
1992 5
1993 4
1994 2
1995 1
2001 1
2011 1
2012 3
2013 1
2017 2
2018 3
2019 3
2020 1
2021 1
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: celano p. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: celano p. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584549 Clinical Trial.
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Singh N, et al. Among authors: celano p. J Clin Oncol. 2022 Oct 1;40(28):3310-3322. doi: 10.1200/JCO.22.00824. Epub 2022 Jul 11. J Clin Oncol. 2022. PMID: 35816666 Updated.
ASCO Standards for Safe Handling of Hazardous Drugs.
Celano P, Kennedy EB, Oliver TK, Zon RT. Celano P, et al. J Oncol Pract. 2019 Feb;15(2):65-66. doi: 10.1200/JOP.18.00701. Epub 2019 Jan 22. J Oncol Pract. 2019. PMID: 30668220 No abstract available.
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Singh N, et al. Among authors: celano p. J Clin Oncol. 2022 Oct 1;40(28):3323-3343. doi: 10.1200/JCO.22.00825. Epub 2022 Jul 11. J Clin Oncol. 2022. PMID: 35816668 Updated.
Safe Handling of Hazardous Drugs: ASCO Standards.
Celano P, Fausel CA, Kennedy EB, Miller TM, Oliver TK, Page R, Ward JC, Zon RT. Celano P, et al. J Clin Oncol. 2019 Mar 1;37(7):598-609. doi: 10.1200/JCO.18.01616. Epub 2019 Jan 8. J Clin Oncol. 2019. PMID: 30620670
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA. Owen DH, et al. Among authors: celano p. J Clin Oncol. 2023 Feb 10;41(5):e10-e20. doi: 10.1200/JCO.22.02124. Epub 2022 Dec 19. J Clin Oncol. 2023. PMID: 36534938
56 results